Lindsey focuses her practice on public and private mergers and acquisitions, including cross-border transactions, joint ventures, earn-outs and other complex transactions, representing strategic and financial buyers as well as sellers. She has represented clients across a variety of industries, including life sciences, technology, healthcare, diagnostics and financial services.
Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology
December 23, 2024
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
Tempus Announces $600 Million Acquisition of Ambry Genetics
November 4, 2024
Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its agreement to acquire Ambry Genetics, a company focusing on genetic testing that aims to improve health by understanding the relationship between genetics and disease.
Propella Therapeutics Enters Merger Agreement With Astellas Pharma
November 16, 2023
Cooley advised Propella Therapeutics, a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs, on its merger agreement with Astellas Pharma in which Astellas will acquire Propella through a US subsidiary.
Travere Sells Bile Acid Product Portfolio to Mirum
July 18, 2023
Cooley advised Travere Therapeutics, a biopharmaceutical company, on its definitive agreement to sell its bile acid product portfolio to Mirum Pharmaceuticals.
